CURRICULUM VITAE

Name and Surname: Diana Ferraro

Date of birth: 18/03/1978

Place of birth: Sorengo (Switzerland)

Citizenship: Italian

E-mail: diana.ferraro@unimore.it

EDUCATION AND ACADEMIC EXPERIENCE

· 2003: Degree in Medicine (110/110 cum laude) at the Catholic University in Rome, Italy.

· 2008: Specialization in Neurology (50/50 cum laude) at the Catholic University in Rome, Italy.

· 2009-2011: Research grant at the Department of Neurosciences of the University of Modena and Reggio Emilia, Modena, for the study of prognostic factors in Multiple Sclerosis

· 2011-2013: PhD student in Neurosciences at the University of Modena and Reggio Emilia, Modena. Thesis on the role of cerebrospinal fluid oligoclonal IgM bands in predicting conversion to Multiple Sclerosis in patients with Clinically Isolated Syndrome

· 2/3/2015-1/3/2020 and since 16/11/2020: Researcher in Neurology at the Department of Biomedical, Metabolic and Neurosciences of the University of Modena and Reggio Emilia, Modena.

WORK EXPERIENCE

Since 1/02/2009: Neurology consultant in the Neurology Unit of the Nuovo Ospedale Civile Sant'Agostino Estense, Modena.

CLINICAL AND RESEARCH INTERESTS

Since 2009, the main clinical and research interest has focused on Multiple Sclerosis and, in particular, on the study of biological markers of diagnosis and prognosis. Prior to that (2003-2008), the main area of clinical and research interest included headaches (in particular chronic headaches and Medication Overuse headache) and other pain syndromes.

TRAINING PROGRAMS/EDITORIAL ACTIVITY

· January 2008-October 2008: Educational project on the study of the human somatosensorial/nociceptive system using functional Magnetic Resonance Imaging at the Department of Biomedical Sciences of the University of Modena and Reggio Emilia, Modena (tutor: Prof. C. A. Porro).

· March 2010 - December 2010: Training program in Applied statistics (duration 10 months, 400 hours) held by Prof. Roberto D'Amico at the University of Modena and Reggio Emilia, Modena. Final examination: 110/110 points.

· March 2014-October 2014: Training program in Cochrane Systematic Reviews and Meta-analyses (84 hours) held by Prof. Roberto D'Amico at the University of Modena and Reggio Emilia, Modena.

LANGUAGES

Italian, English, German

FUNDING OF RESEARCH PROJECTS /PRIZES

· 2011: Co-investigator of project on “Polyfunctionality of peripheral iNKT cells as an immunological marker of different forms of Multiple Sclerosis” - pilot project - funded by Fondazione Italiana Sclerosi Multipla (FISM) (PI: Prof. Andrea Cossarizza, University of Modena and Reggio Emilia, Modena).

· 2012: Co-investigator of project on “Polyfunctionality of peripheral iNKT cells as an immunological marker of different forms of Multiple Sclerosis and following different treatments” funded by Fondazione Italiana Sclerosi Multipla (FISM) (PI: Prof. Andrea Cossarizza, University of Modena and Reggio Emilia, Modena).

· 2014: Co-investigator of pilot project on "Respiration and glycolysis in lymphocytes from

· patients with different forms of Multiple Sclerosis funded by Fondazione Italiana Sclerosi Multipla (FISM) (PI: Prof. Marcello Pinti, University of Modena and Reggio Emilia, Modena).

· 2016: Co-investigator of full project on “Regulation of cell metabolism in lymphocytes from patients with progressive forms of multiple sclerosis” funded by Fondazione Italiana Sclerosi Multipla (FISM) (PI: Prof. Marcello Pinti, University of Modena and Reggio Emilia, Modena).

· 2018: Co-investigator. Project on “Mitochondrial DAMPs – a pilot study” funded by Fondazione Italiana Sclerosi Multipla (FISM) (PI: Prof. Andrea Cossarizza, University of Modena and Reggio Emilia, Modena).

· Poster Prize “Best in Class” at Congress “Experience with oral therapies in MS” in Mestre (September 2013). Role: last author.

· “Outstanding poster award” at the “30th Congress of the International Society for Advancement of Cytometry” (Glasgow, June 2015). Role: co-author.

· Poster Prize at the “XLVIII Congress of the Italian Neurological Society” (Naples, October 2017). Role: co-author.

TEACHING ACTIVITY

Since Academic year 2016/2017:

· Clinical medical sciences 2; Degree Course: DIETETICS; Department of Diagnostic Medicine, Clinical and Health public, University of Modena and Reggio Emilia

· Diseases of the nervous system; Single-Cycle Master Degrees: MEDICINE AND SURGERY (D.M.270/04)

Department of Biomedical, Metabolical and Neurosciences; University of Modena and Reggio Emilia

· Nursing in chronicity; Degree Course: NURSING (REGGIO EMILIA) (D.M.270/04)

Department of Surgical, Medical, Dental and Morphological Sciences with Interest transplant, Oncological and Regenerative Medicine; University of Modena and Reggio Emilia

Since Academic year 2018/2019

· Member of the Faculty Board of the Neuroscience Doctorate of the University of Modena and Reggio Emilia.

COLLABORATIONS

· CO-PRINCIPAL INVESTIGATOR, for the MS Center of Modena, Italy of the "MSBase Neuroimmunology

Registry"

· Collaborator of the Italian MS Registry

· Collaborator of the "Emilia-Romagna network for Multiple Sclerosis" (ERMES)

· Member of the Scientific Committee of the Italian Research Group RIREMS ("Rising Researchers in Multiple Sclerosis).

OTHER ACTIVITIES

· Reviewer for international peer-reviewed journals including Multiple Sclerosis Journal, Journal of Neurology Neurosurgery and Psychiatry, European Journal of Neurology, Journal of the Neurological Sciences, BMC Neurology, Journal of Neuroimmunology, Frontiers in Immunology, Annals of Clinical and Translational Neurology, Multiple Sclerosis and Demyelinating Disorders, Drugs of the future, Molecular Diagnosis and Therapy, Cells, Journal of Central Nervous System Disease, Pain Management, Biomedicines

· Associate Editor of BMC Neurology (impact factor: 2.474; 5-year impact factor: 2.993).

PUBLISHED ARTICLESPUBBLICAZIONI (solo articoli in extenso)

1. Ferraro D. Iaffaldano P.Guerra T. et al on behalf of the Italian MS Register. Risk of Multiple Sclerosis relapses when switching from fingolimod to cell-depleting agents: the role of washout duration. J Neurol. 2021 Jul 22. doi: 10.1007/s00415-021-10708-1. Online ahead of print.

2. Nasi M, De Gaetano A, Bianchini E, et al. Mitochondrial damage-associated molecular patterns stimulate reactive oxygen species production in human microglia. Mol Cell Neurosci. 2020;108
3. Andersen JB, Sharmin S, Lefort M, et al. The effectiveness of natalizumab vs fingolimod–A comparison of international registry studies. Mult Scler Relat Disord. 2021;53. doi:10.1016/J.MSARD.2021.103012
4. Baldin E, Zenesini C, Antonazzo IC, et al. Antibiotic Use and Risk of Multiple Sclerosis: A Nested Case-Control Study in Emilia-Romagna Region, Italy. Neuroepidemiology. 2021;55(3):224-231. doi:10.1159/000515682
5. Baroncini D, Simone M, Iaffaldano P, et al. Risk of Persistent Disability in Patients with Pediatric-Onset Multiple Sclerosis. JAMA Neurol. 2021;78(6):726-735. doi:10.1001/JAMANEUROL.2021.1008
6. Pinti M, Ferraro D, Nasi M. Microglia activation: A role for mitochondrial DNA? Neural Regen Res. 2021;16(12):2393-2394. doi:10.4103/1673-5374.313034
7. Zanghì A, Gallo A, Avolio C, et al. Exit Strategies in Natalizumab-Treated RRMS at High Risk of Progressive Multifocal Leukoencephalopathy: a Multicentre Comparison Study. Neurotherapeutics. Published online 2021. doi:10.1007/S13311-021-01037-2
8. Ferraro D, Annovazzi P, Lanzillo R, et al. A multicenter survey on access to care in Multiple Sclerosis-related trigeminal neuralgia. J Neurol Sci. 2021;424. doi:10.1016/J.JNS.2021.117430
9. Chan A, Rose J, Alvarez E, et al. Lymphocyte reconstitution after DMF discontinuation in clinical trial and real-world patients with MS. Neurol Clin Pract. 2020;10(6):510-519. doi:10.1212/CPJ.0000000000000800
10. Roos I, Leray E, Frascoli F, et al. Determinants of therapeutic lag in multiple sclerosis. Mult Scler. Published online January 11, 2021:1352458520981300. doi:10.1177/1352458520981300
11. Kalincik T, Diouf I, Sharmin S, et al. Effect of Disease Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years. Neurology. Published online December 28, 2020:10.1212/WNL.0000000000011242. doi:10.1212/wnl.0000000000011242
12. Di Gregorio M, Torri Clerici VLA, Fenu G, et al. Defining the course of tumefactive multiple sclerosis: A large retrospective multicentre study. Eur J Neurol. Published online 2020. doi:10.1111/ene.14672
13. Iaffaldano P, Lucisano G, Patti F, et al. Transition to secondary progression in relapsing-onset multiple sclerosis: Definitions and risk factors. Mult Scler. Published online November 19, 2020:1352458520974366. doi:10.1177/1352458520974366
14. Ferraro D, Bedin R, Natali P, et al. Kappa index versus CSF oligoclonal bands in predicting multiple sclerosis and infectious/inflammatory CNS disorders. Diagnostics. 2020;10(10). doi:10.3390/diagnostics10100856
15. Bovis F, Kalincik T, Lublin F, et al. Treatment Response Score to Glatiramer Acetate or Interferon Beta-1a. Neurology. 2021;96(2):e214-e227.
16. Mariotto S, Ferraro D, Soldani F, et al. Inter-center agreement in the interpretation of oligoclonal bands. Clin Chem Lab Med. Published online 2020. doi:10.1515/cclm-2020-1037
17. Plantone D, Vollono C, Pardini M, (….) and Ferraro D. A voxel-based lesion symptom mapping analysis of chronic pain in multiple sclerosis. Neurol Sci. 2021;42(5):1941-1947.
18. Roos I, Leray E, Frascoli F, et al. Delay from treatment start to full effect of immunotherapies for multiple sclerosis. Brain. 2020;143(9):2742-2756.
19. Tsantes E, Curti E, Ferraro D, et al. Dimethyl fumarate-induced lymphocyte count drop is related to clinical effectiveness in relapsing–remitting multiple sclerosis. Eur J Neurol. Published online 2020. doi:10.1111/ene.14538
20. Nasi M, Bianchini E, De Biasi S, et al. Increased plasma levels of mitochondrial DNA and pro-inflammatory cytokines in patients with progressive multiple sclerosis. J Neuroimmunol. 2020;338(November 2019):577107. doi:10.1016/j.jneuroim.2019.577107

21. Tortorella C, Solaro C, Annovazzi P, et al. Informing MS patients on treatment options: a consensus on the process of consent taking. Neurol Sci. Published online April 2, 2020. doi:10.1007/s10072-020-04339-z
22. Kunchok A, Lechner-Scott J, Granella F, et al. Prediction of on-treatment disability worsening in RRMS with the MAGNIMS score. Mult Scler J. 2021;27(5):695-705.
23. Kalincik T, Lizak N, Malpas CB, et al. Association of Sustained Immunotherapy with Disability Outcomes in Patients with Active Secondary Progressive Multiple Sclerosis. JAMA Neurol. 2020;77(11):1398-1407.
24. Gastaldi M, Scaranzin S, Jarius S, et al. Cell-based assays for the detection of MOG antibodies: a comparative study. J Neurol. 2020;267(12):3555-3564.
25. Malpas CB, Manouchehrinia A, Sharmin S, Roos I, Horakova D, Havrdova EK, et al. Early clinical markers of aggressive multiple sclerosis. Brain. 2020 May 1;143(5):1400-1413. doi: 10.1093/brain/awaa081.Brain. 2020.
26. Orlandi R, Mariotto S, Ferrari S, Gobbin F, Sechi E, Capra R, et al. Diagnostic features of initial demyelinating events associated with serum MOG-IgG. J Neuroimmunol. 2020 Jul 15;344:577260. doi: 10.1016/j.jneuroim.2020.577260.
27. Le M, Malpas C, Sharmin S, Horáková D, Havrdova E, Trojano M, Izquierdo G, et al., Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis. Mult Scler. 2020 Jun 15:1352458520926955. doi: 10.1177/1352458520926955.
28. Ferraro D, Guicciardi C, De Biasi S, Pinti M, Bedin R, Camera V, et al. Plasma neurofilaments correlate with disability in progressive multiple sclerosis patients. Acta Neurol Scand 2019:ane.13152. https://doi.org/10.1111/ane.13152.
29. He A, Merkel B, Brown JWL, Zhovits Ryerson L, Kister I, Malpas CB, et al. Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. Lancet Neurol 2020;19:307–16. https://doi.org/10.1016/S1474-4422(20)30067-3.
30. Ferraro D, Trovati A, Bedin R, Natali P, Franciotta D, Santangelo M, et al. Cerebrospinal fluid free light kappa and lambda chains in oligoclonal band-negative patients with suspected Multiple Sclerosis. Eur J Neurol 2019:1–7. https://doi.org/10.1111/ene.14121.
31. Tortorella C, Solaro C, Annovazzi P, Boffa L, Buscarinu MC, Buttari F, et al. Informing MS patients on treatment options: a consensus on the process of consent taking. Neurol Sci 2020. https://doi.org/10.1007/s10072-020-04339-z.
32. Chiarini M, Capra R, Serana F, Bertoli D, Sottini A, Giustini V, et al. Simultaneous quantification of natural and inducible regulatory T-cell subsets during interferon-β therapy of multiple sclerosis patients. J Transl Med 2020;18:169. https://doi.org/10.1186/s12967-020-02329-5.
33. Fambiatos A, Jokubaitis V, Horakova D, Kubala Havrdova E, Trojano M, Prat A, et al. Risk of secondary progressive multiple sclerosis: A longitudinal study. Mult Scler J 2019:135245851986899. https://doi.org/10.1177/1352458519868990.
34. Calabrese M, Gasperini C, Tortorella C, Schiavi G, Frisullo G, Ragonese P, et al. “Better explanations” in multiple sclerosis diagnostic workup. Neurology 2019;92:e2527–37. https://doi.org/10.1212/WNL.0000000000007573.
35. Solari A, Giovannetti AM, Giordano A, Tortorella C, Clerici VT, Brichetto G, et al. Conversion to secondary progressive multiple sclerosis: Patient awareness and needs. Results from an online survey in Italy and Germany. Front Neurol 2019;10:1–10. https://doi.org/10.3389/fneur.2019.00916.
36. Kalincik T, Kubala Havrdova E, Horakova D, Izquierdo G, Prat A, Girard M, et al. Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis. J Neurol Neurosurg Psychiatry 2019:jnnp-2018-319831. https://doi.org/10.1136/jnnp-2018-319831.
37. Brown JWL, Coles A, Horakova D, Havrdova E, Izquierdo G, Prat A, et al. Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis. JAMA 2019;321:175–87. https://doi.org/10.1001/jama.2018.20588.

38. Kunchok A, Malpas C, Nytrova P, Havrdova EK, Alroughani R, Terzi M, et al. Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorder. Mult Scler Relat Disord 2020;38:101868. https://doi.org/10.1016/j.msard.2019.101868.
39. Nasi M, Bianchini E, De Biasi S, Gibellini L, Neroni A, Mattioli M, et al. Increased plasma levels of mitochondrial DNA and pro-inflammatory cytokines in patients with progressive multiple sclerosis. J Neuroimmunol 2020;338:577107. https://doi.org/10.1016/j.jneuroim.2019.577107.
40. De Biasi S, Simone AM, Bianchini E, Lo Tartaro D, Pecorini S, Nasi M, et al. Mitochondrial functionality and metabolism in T cells from progressive multiple sclerosis patients. Eur J Immunol 2019:1–18. https://doi.org/10.1002/eji.201948223.
41. Vollono C, Della Marca G, Testani E, Losurdo A, Virdis D, Ferraro D, et al. Abnormal Circadian Modification of Aδ-Fiber Pathway Excitability in Idiopathic Restless Legs Syndrome. Pain Res Manag 2019;2019:5408732. https://doi.org/10.1155/2019/5408732.
42. Curti E, Tsantes E, Baldi E, Caniatti LM, Ferraro D, Sola P, et al. The real-world effectiveness of natalizumab and fingolimod in relapsing-remitting multiple sclerosis. An Italian multicentre study. Mult Scler Relat Disord 2019;33:146–52. https://doi.org/10.1016/j.msard.2019.05.026.
43. Ferraro D, Annovazzi P, Moccia M, Lanzillo R, De Luca G, Nociti V, et al. Characteristics and treatment of Multiple Sclerosis-related trigeminal neuralgia: An Italian multi-centre study. Mult Scler Relat Disord 2020;37. https://doi.org/10.1016/j.msard.2019.101461.
44. Nguyen A-L, Havrdova EK, Horakova D, Izquierdo G, Kalincik T, van der Walt A, et al. Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study. Mult Scler Relat Disord 2019;28:235–43. https://doi.org/10.1016/j.msard.2019.01.003.
45. Lorscheider J, Kuhle J, Izquierdo G, Lugaresi A, Havrdova E, Horakova D, et al. Anti-inflammatory disease-modifying treatment and disability progression in primary progressive multiple sclerosis: a cohort study. Eur J Neurol 2018. https://doi.org/10.1111/ene.13824.
46. Ferraro D, Camera V, Baldi E, Vacchiano V, Curti E, Guareschi A, et al. First-line disease-modifying drugs in relapsing–remitting multiple sclerosis: an Italian real-life multicenter study on persistence. Curr Med Res Opin 2018;34:1803–7. https://doi.org/10.1080/03007995.2018.1451311.
47. Kister I, Spelman T, Patti F, Duquette P, Trojano M, Izquierdo G, et al. Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy. J Neurol Sci 2018;391:72–6. https://doi.org/10.1016/j.jns.2018.06.001.
48. Hughes J, Jokubaitis V, Lugaresi A, Hupperts R, Izquierdo G, Prat A, et al. Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple Sclerosis. JAMA Neurol 2018;75:1407. https://doi.org/10.1001/jamaneurol.2018.2109.
49. Ferraro D, Camera V, Vitetta F, Zennaro M, Ciolli L, Nichelli PF, et al. Acute coronary syndrome associated with alemtuzumab infusion in multiple sclerosis. Neurology 2018;90:852–4. https://doi.org/10.1212/WNL.0000000000005417.
50. Fasano A, Fini N, Ferraro D, Ferri L, Vinceti M, Mandrioli J. Percutaneous endoscopic gastrostomy, body weight loss and survival in amyotrophic lateral sclerosis: a population-based registry study. Amyotroph Lateral Scler Frontotemporal Degener 2017:1–10. https://doi.org/10.1080/21678421.2016.1270325.
51. Frau J, Villar LM, Sardu C, Secci MA, Schirru L, Ferraro D, et al. Intrathecal oligoclonal bands synthesis in multiple sclerosis: is it always a prognostic factor? J Neurol 2017. https://doi.org/10.1007/s00415-017-8716-4.
52. Bianchini E, De Biasi S, Simone AM, Ferraro D, Sola P, Cossarizza A, et al. Invariant natural killer T cells and mucosal-associated invariant T cells in multiple sclerosis. Immunol Lett 2017;183:1–7. https://doi.org/10.1016/j.imlet.2017.01.009.

53. Giovannini G, Cavallieri F, Meletti S, Chiari A, Mandrioli J, Ferraro D, et al. Acute hemichorea as unusual first multiple sclerosis presentation. Neurol Clin Pract 2017;7. https://doi.org/10.1212/CPJ.0000000000000279.
54. Rosafio F, Lelli N, Mimmi S, Vandelli L, Bigliardi G, Dell'Acqua ML, et al. Platelet Function Testing in Patients with Acute Ischemic Stroke: An Observational Study. J Stroke Cerebrovasc Dis 2017;26. https://doi.org/10.1016/j.jstrokecerebrovasdis.2017.04.023.
55. Franciotta D, Gastaldi M, Benedetti L, Garnero M, Biagioli T, Brogi M, et al. Diagnostics of anti-MAG antibody polyneuropathy. Neurol Sci 2017;38. https://doi.org/10.1007/s10072-017-3024-4.
56. Ferraro D, Plantone D, Morselli F, Dallari G, Simone AM, Vitetta F, et al. Systematic Assessment and characterization of chronic pain in multiple sclerosis patients. Neurol Sci 2017. https://doi.org/10.1007/s10072-017-3217-x.
57. Ferraro D, Franciotta D, Bedin R, Solaro C, Cocco E, Santangelo M, et al. A multicenter study on the diagnostic significance of a single cerebrospinal fluid IgG band. J Neurol 2017;264:973–8. https://doi.org/10.1007/s00415-017-8480-5.
58. Kalincik T, Jokubaitis V, Spelman T, Horakova D, Havrdova E, Trojano M, et al. Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosis. Mult Scler J 2017. https://doi.org/10.1177/1352458517728812.
59. Franciotta D, Gastaldi M, Benedetti L, Pesce G, Biagioli T, Lolli F, et al. Diagnostics of dysimmune peripheral neuropathies. Neurol Sci 2017;38:243–7. https://doi.org/10.1007/s10072-017-3025-3.
60. De Biasi S, Simone AM, Nasi M, Bianchini E, Ferraro D, Vitetta F, et al. iNKT Cells in Secondary Progressive Multiple Sclerosis Patients Display Pro-inflammatory Profiles. Front Immunol 2016;7:555. https://doi.org/10.3389/fimmu.2016.00555.
61. Ferraro D, Galli V, Simone AM, Bedin R, Vitetta F, Merelli E, et al. Cerebrospinal fluid anti-Epstein-Barr virus specific oligoclonal IgM and IgG bands in patients with clinically isolated and Guillain-Barré syndrome. J Neurovirol 2016. https://doi.org/10.1007/s13365-016-0493-9.
62. Ferraro D, Consonni D, Fini N, Fasano A, Del Giovane C, Mandrioli J, et al. Amyotrophic lateral sclerosis: a comparison of two staging systems in a population-based study. Eur J Neurol 2016;23:1426–32. https://doi.org/10.1111/ene.13053.
63. Ferraro D, Simone AM, Adani G, Vitetta F, Mauri C, Strumia S, et al. Definitive childlessness in women with multiple sclerosis: a multicenter study. Neurol Sci 2017;38. https://doi.org/10.1007/s10072-017-2999-1.
64. Fainardi E, Bortolotti D, Bolzani S, Castellazzi M, Tamborino C, Roversi G, et al. Cerebrospinal fluid amounts of HLA-G in dimeric form are strongly associated to patients with MRI inactive multiple sclerosis. Mult Scler 2016;22:245–9. https://doi.org/10.1177/1352458515590647.
65. Rizzo R, Pietrobon S, Mazzoni E, Bortolotti D, Martini F, Castellazzi M, et al. Serum IgG against Simian Virus 40 antigens are hampered by high levels of sHLA-G in patients affected by inflammatory neurological diseases, as multiple sclerosis. J Transl Med 2016;14:216. https://doi.org/10.1186/s12967-016-0981-y.
66. Ferraro D, Mirante VG, Losi L, Villa E, Simone AM, Vitetta F, et al. Methylprednisolone-induced Toxic Hepatitis After Intravenous Pulsed Therapy for Multiple Sclerosis Relapses. Neurologist 2015;19:153–4. https://doi.org/10.1097/NRL.0000000000000029.
67. Trentini A, Manfrinato MC, Castellazzi M, Tamborino C, Roversi G, Volta CA, et al. TIMP-1 resistant matrix metalloproteinase-9 is the predominant serum active isoform associated with MRI activity in patients with multiple sclerosis. Mult Scler 2015. https://doi.org/10.1177/1352458514560925.
68. Ferraro D, Galli V, Vitetta F, Simone AM, Bedin R, Del Giovane C, et al. Cerebrospinal fluid CXCL13 in clinically isolated syndrome patients: Association with oligoclonal IgM bands and prediction of Multiple Sclerosis diagnosis. J Neuroimmunol 2015;283:64–9. https://doi.org/10.1016/j.jneuroim.2015.04.011.

69. Simone AM, Ferraro D, Vitetta F, Marasca R, Bonacorsi G, Pinelli G, et al. Severe anemia in a patient with multiple sclerosis treated with natalizumab. Neurology 2014;83. https://doi.org/10.1212/WNL.0000000000000614.
70. Nasi M, Pinti M, De Biasi S, Gibellini L, Ferraro D, Mussini C, et al. Aging with HIV infection: A journey to the center of inflammAIDS, immunosenescence and neuroHIV. Immunol Lett 2014. https://doi.org/10.1016/j.imlet.2014.06.012.
71. Baldi E, Guareschi A, Vitetta F, Senesi C, Curti E, Montepietra S, et al. Previous treatment influences fingolimod efficacy in relapsing-remitting multiple sclerosis: Results from an observational study. Curr Med Res Opin 2014;30. https://doi.org/10.1185/03007995.2014.921144.
72. Codeluppi L, Ferraro D, Marudi A, Valzania F. False positive absent somatosensory evoked potentials in cardiac arrest with therapeutic hypothermia. Resuscitation 2014;85. https://doi.org/10.1016/j.resuscitation.2014.08.012.
73. Ferraro D, Federzoni L, Vitetta F, Simone A, Cossarizza A, Nichelli P, et al. Frequent early multiple sclerosis relapses during treatment with fingolimod: a paradoxical effect? Mult Scler 2013;19:1550. https://doi.org/10.1177/1352458513490549.
74. Ferraro D, De Biasi S, Vitetta F, Simone AM, Federzoni L, Borghi V, et al. Recurrent varicella following steroids and fingolimod in a Multiple Sclerosis patient. J Neuroimmune Pharmacol 2013;8:1059–61. https://doi.org/10.1007/s11481-013-9510-4.
75. Ferraro D, Simone AM, Bedin R, Galli V, Vitetta F, Federzoni L, et al. Cerebrospinal fluid oligoclonal IgM bands predict early conversion to clinically definite multiple sclerosis in patients with Clinically Isolated Syndrome. J Neuroimmunol 2013;257. https://doi.org/10.1016/j.jneuroim.2013.01.011.
76. Antonelli T, Tomasini MC, Castellazzi M, Sola P, Tamborino C, Ferraro D, et al. Biological markers in cerebrospinal fluid for axonal impairment in multiple sclerosis: Acetylcholinesterase activity cannot be considered a useful biomarker. Neurol Sci 2013;34. https://doi.org/10.1007/s10072-012-1265-9.
77. Zini A, Fioravanti V, Ferraro D, Casoni F, Cavazzuti M, Nichelli P. Paroxysmal ventricular tachicardia and pure right insular stroke. J Cardiovasc Med 2012;13. https://doi.org/10.2459/JCM.0b013e32834f241d.
78. Ferraro D, Vollono C, Miliucci R, Virdis D, De Armas L, Pazzaglia C, et al. Habituation to pain in “medication overuse headache”: A CO2 laser-evoked potential study. Headache 2012;52. https://doi.org/10.1111/j.1526-4610.2012.02151.x.
79. Sola P, Mandrioli J, Simone AM, Ferraro D, Bedin R, Annecca R, et al. Primary progressive versus relapsing-onset multiple sclerosis: presence and prognostic value of cerebrospinal fluid oligoclonal IgM. Mult Scler 2011;17:303–11. https://doi.org/10.1177/1352458510386996.
80. Ferraro D, Simone AM, Merelli E, Mandrioli J, Molinari MA, Nichelli PF, et al. Isolated progressive cognitive impairment and depression in a patient with neuroradiological features suggestive of multiple sclerosis. Neurol Sci 2011;32. https://doi.org/10.1007/s10072-011-0581-9.
81. Giulietti G, Summers PE, Ferraro D, Porro CA, Maraviglia B, Giove F. Semiautomated segmentation of the human spine based on echoplanar images. Magn Reson Imaging 2011;29. https://doi.org/10.1016/j.mri.2011.08.006.
82. Valeriani M, Pazzaglia C, Ferraro D, Virdis D, Rotellini S, Le Pera D, et al. Evidence of different spinal pathways for the warmth evoked potentials. Clin Neurophysiol 2011;122. https://doi.org/10.1016/j.clinph.2011.04.023.
83. Georgoulopoulou E, Vinceti M, Bonvicini F, Sola P, Goldoni CA, De Girolamo G, et al. Changing incidence and subtypes of ALS in Modena, Italy: A 10-years prospective study. Amyotroph Lateral Scler 2011;12:451–7. https://doi.org/10.3109/17482968.2011.593037.

84. Vollono C, Ferraro D, Miliucci R, Vigevano F, Valeriani M. The abnormal recovery cycle of somatosensory evoked potential components in children with migraine can be reversed by topiramate. Cephalalgia 2010;30:17–26. https://doi.org/10.1111/j.1468-2982.2009.01892.x.
85. Pazzaglia C, Vollono C, Ferraro D, Virdis D, Lupi V, Le Pera D, et al. Mechanisms of neuropathic pain in patients with Charcot-Marie-Tooth 1 A: a laser-evoked potential study. Pain 2010;149:379–85. https://doi.org/10.1016/j.pain.2010.03.001.
86. Summers PE, Ferraro D, Duzzi D, Lui F, Iannetti GD, Porro CA. A quantitative comparison of BOLD fMRI responses to noxious and innocuous stimuli in the human spinal cord. Neuroimage 2010;50. https://doi.org/10.1016/j.neuroimage.2010.01.043.
87. Della Marca G, Vollono C, Ferraro D, Mariotti P, Mazza M, Ferini-Strambi L, et al. Left thalamomegaly in a patient with partial epilepsy. Clin Neurol Neurosurg 2008;110. https://doi.org/10.1016/j.clineuro.2007.10.021.
88. Ferraro D, Di Trapani G. Topiramate in the prevention of pediatric migraine: literature review. J Headache Pain 2008;9:147–50. https://doi.org/10.1007/s10194-008-0030-1.
89. Padua L, Cavallaro T, Pareyson D, Quattrone A, Vita G, Schenone A, et al. Charcot-Marie-Tooth and pain: Correlations with neurophysiological, clinical, and disability findings. Neurol Sci 2008;29. https://doi.org/10.1007/s10072-008-0935-0.
90. Fasano A, Natoli GF, Cianfoni A, Ferraro D, Loria G, Bentivoglio AR, et al. Acute necrotizing encephalopathy: A relapsing case in a European adult [4]. J Neurol Neurosurg Psychiatry 2008;79. https://doi.org/10.1136/jnnp.2007.127670.
91. Granata G, Martinoli C, Pazzaglia C, Caliandro P, Padua L, Ferraro D. Letter to Editor: Carpal tunnel syndrome due to an atypical deep soft tissue leiomyoma: The risk of misdiagnosis and mismanagement. World J Surg Oncol 2008;6. https://doi.org/10.1186/1477-7819-6-22.
92. Vollono C, Ferraro D, Valeriani M. Antiepileptic drugs in the preventive treatment of migraine in children and adolescents. Drug Dev Res 2007;68. https://doi.org/10.1002/ddr.20201.
93. Mei D, Ferraro D, Zelano G, Capuano A, Vollono C, Gabriele C, et al. Topiramate and triptans revert chronic migraine with medication overuse to episodic migraine. Clin Neuropharmacol 2006;29. https://doi.org/10.1097/01.WNF.000022888.49044.99.
94. Vollono C, Capuano A, Mei D, Ferraro D, Pierguidi L, Evangelista M, et al. Multiple attack study on the available triptans in Italy versus placebo. Eur J Neurol 2005;12:557–63. https://doi.org/10.1111/j.1468-1331.2005.01030.x.
95. Mei D, Capuano a, Vollono C, Evangelista M, Ferraro D, Tonali P, et al. Topiramate in migraine prophylaxis: a randomised double-blind versus placebo study. Neurol Sci 2004;25:245–50. https://doi.org/10.1007/s10072-004-0350-0.
96. Di Trapani G, Mei D, Vollono C, Capuano A, Ferraro D. Antiepileptic drugs in the treatment of headache: Neuroprotective effect or something else? J Headache Pain 2004;5. https://doi.org/10.1007/s10194-004-0124-3.
97. Capuano A, Vollono C, Mei D, Pierguidi L, Ferraro D, Di Trapani G. Antiepileptic drugs in migraine prophylaxis: state of the art. Clin Ter 155:79–87.
98. Magnavita N, Placentino RA, Mei D, Ferraro D, Di Trapani G. Occupational head injury and subsequent glioma. Neurol Sci 2003;24. https://doi.org/10.1007/s100720300018.

Data 29/07/2021 Signature